Sumitomo Mitsui Trust Holdings Inc. Decreases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Holdings Inc. lessened its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 4.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,320,652 shares of the biotechnology company’s stock after selling 67,922 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Arcturus Therapeutics were worth $41,640,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its holdings in Arcturus Therapeutics by 224.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 114,810 shares of the biotechnology company’s stock valued at $3,620,000 after purchasing an additional 79,387 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in shares of Arcturus Therapeutics by 3.0% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 43,889 shares of the biotechnology company’s stock valued at $1,401,000 after buying an additional 1,272 shares in the last quarter. Tritonpoint Wealth LLC purchased a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at about $885,000. Arizona State Retirement System acquired a new position in Arcturus Therapeutics during the 4th quarter worth approximately $211,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Arcturus Therapeutics by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 2,406 shares during the period. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

ARCT opened at $25.98 on Friday. Arcturus Therapeutics Holdings Inc. has a 1-year low of $17.52 and a 1-year high of $43.81. The company has a 50-day moving average of $35.19 and a 200-day moving average of $29.73. The company has a market capitalization of $699.25 million, a P/E ratio of -24.98 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The firm had revenue of $33.99 million during the quarter, compared to analyst estimates of $64.14 million. As a group, sell-side analysts expect that Arcturus Therapeutics Holdings Inc. will post -1.42 earnings per share for the current fiscal year.

Insider Activity at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 17,435 shares of Arcturus Therapeutics stock in a transaction on Monday, March 25th. The shares were sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the transaction, the chief operating officer now owns 473,448 shares of the company’s stock, valued at $16,580,148.96. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 13.80% of the company’s stock.

Analysts Set New Price Targets

ARCT has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. Citigroup boosted their price objective on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $61.33.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.